Drug intelligence / Profile preview

AAV-hIR

Development stage: Preclinical
Lead developer: Chinese Academy of Sciences
Modality: Gene Therapies
Administration: Intravenous

Overview

AAV-hIR is an experimental gene therapy candidate designed to deliver the human insulin receptor (hIR) gene to metabolic tissues, primarily the liver. It utilizes an adeno-associated virus (AAV) vector, specifically the AAV8 serotype, to restore or increase the expression of insulin receptors. This approach is intended to overcome insulin resistance and improve glucose homeostasis in patients with Type 2 Diabetes Mellitus (T2DM). Preclinical studies in mouse models, including inducible IR-knockout and ob/ob mice, have demonstrated that a single dose of AAV-hIR can significantly improve diabetic phenotypes with a long-lasting profile and a low risk of hypoglycemia in healthy subjects.

Other names: Adeno-associated virus-human insulin receptor

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on AAV-hIR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-hIR.

Explore the full profile